It's great to someone benefitting from this low toxicity approach! Sounds like your onc is working the her2 crosstalk and estrogen as therapy simultaneously. Very cool. It seems many oncs overlook the potential of
ER issues in metastatic BC.
Did the onc give anything other than hunch as reason to try the inverted endocrine approach? Seems like the hard part would be administering meds that will likely feed or inhibit the cancer. Wish there was a simple way to monitor the ER behavior to know when to make the switch. Seems like a lot of mileage could be had if therapy could intelligently alternate between inhibiting and adding Estrogen. There is also suggestion that intermittent use of Femara can be helpful. Again..the hard part is deciding when to pull the plug and plug it back in.
But all this is even more enticing since long term Herceptin can seemingly give rise to ER positivity in previously ER neg tumors. This potentially makes the issue relevant to more than the small % of pathology based Her2/ER+ patients.